Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

Status unconfirmed · Phase 1/Phase 2

Conditions studied: Melanoma (Skin)

In brief

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage II, stage III, or stage IV melanoma.

Key facts

Study ID

NCT00010309

Run by

Genzyme, a Sanofi Company

Starts

2000-11-01

Last updated by the study team

2014-01-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Genzyme Corporation — Cambridge, Massachusetts, United States
• U.S. Oncology — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.